Story
Founded in late 2018, Koru Biotech began with a clear mission: to develop a rapid test for detecting Staphylococcus aureus mastitis in dairy cows.
Through iterative development and customer feedback, the company pivoted to create StaphGold—an ELISA-based laboratory test that detects S. aureus antibodies in milk samples. S. aureus is a leading cause of subclinical mastitis, which contributes to milk loss and quality degradation. Its inconsistent shedding pattern makes detection difficult, but StaphGold has demonstrated over 90% sensitivity and specificity, making it a reliable and cost-effective diagnostic tool. This enables dairy producers to identify infected cows early and make informed decisions about dry cow therapy and herd management.
A breakthrough in mastitis research led Koru to a pivotal discovery: a novel lipopolysaccharide (LPS) complex biomarker with high clinical relevance.
This finding shifted the company’s focus toward developing advanced diagnostics, treatments, and preventive solutions—anchored in a commitment to combat the global challenge of antimicrobial resistance.
Today, Koru Biotech is pioneering novel solutions for infectious bovine diseases, building on two key discoveries:
- A unique biomarker complex indicative of gram-negative infections
- A protective immune complex that helps safeguard newborn calves from diseases caused by these pathogens
Our current R&D portfolio targets the rapid detection and treatment of coliform mastitis and the prevention of enteritis in newborn calves. Koru’s scalable biotech platform holds promise for broader applications in disease management across bovines—and potentially other species, including humans.
What started in the dairy shed is now reshaping the future of bacterial diagnostics.
Building on this foundation, Koru is now developing breakthrough solutions for a wider range of bacterial diseases.